The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA).
 
Van K. Morris
Consulting or Advisory Role - Axiom Healthcare Strategies; Bicara Therapeutics; BioMedical Insights; Boehringer Ingelheim; Incyte
Research Funding - Bicara Therapeutics (Inst); BioNTech (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); Immatics; Pfizer (Inst)
 
Greg Yothers
Employment - Mountainview Pediatrics (I)
Consulting or Advisory Role - Orbus Therapeutics
 
Scott Kopetz
Stock and Other Ownership Interests - Frontier Medicines; Iylon; Lutris; Navire; Xilis
Consulting or Advisory Role - Abbvie; Accademia Nazionale Di Medicina (ACCMED); Amal Therapeutics; Amgen; AstraZeneca/MedImmune; Bayer Health; Bicara Therapeutics; Black Diamond Therapeutics; Boehringer Ingelheim; Bristol-Myers Squibb/Medarex; Cardiff Oncology; Carina Biotech; CureTeq; EMD Serono; Endeavor BioMedicines; Flame Biosciences; Foundation Medicine; Frontier Medicines; Genentech; Genomic Health; Gilead Sciences; GlaxoSmithKline; HalioDx; Harbinger Oncology, Inc; Holy Stone Healthcare; Inivata; Ipsen; Iylon; Jacobio; Jazz Pharmaceuticals; Johnson & Johnson/Janssen; Lilly; Lutris; Merck; Mirati Therapeutics; NeoGenomics Laboratories; Novartis; Numab; Ono Pharmaceutical; Pfizer; Redx Pharma; Repare Therapeutics; Replimune; Servier; Taiho Pharmaceutical; Takeda; Tempus; Xilis; Zentalis
Research Funding - Amgen; Array BioPharma; Biocartis; Daiichi Sankyo; EMD Serono; Genentech/Roche; Guardant Health; Lilly; MedImmune; Novartis; Sanofi
 
Samuel A. Jacobs
Employment - Exact Sciences
Consulting or Advisory Role - Exact Sciences
 
Peter C. Lucas
Stock and Other Ownership Interests - Amgen
Honoraria - Schrodinger (I)
Patents, Royalties, Other Intellectual Property - Patent No PCT/US2022/021720, "Small molecules and their use as MALT1 inhibitors"
 
Atif Iqbal
No Relationships to Disclose
 
Patrick M Boland
Consulting or Advisory Role - Bayer; Guardant Health; Merck; Pfizer
Research Funding - Amgen (Inst); Macrogenics (Inst); Merck (Inst); Processa Pharmaceuticals (Inst)
 
Dustin A. Deming
Consulting or Advisory Role - Bayer; Lilly; Pfizer; Seagen
Research Funding - AADi (Inst); Arcus Ventures (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Curegenix (Inst); Genentech (Inst); Lilly (Inst); Merck (Inst); Millennium (Inst); Natera (Inst); Promega (Inst); Revolution Medicines (Inst); Strata Oncology (Inst)
 
Aaron James Scott
Stock and Other Ownership Interests - Johnson & Johnson/Janssen
Consulting or Advisory Role - Exelixis; Pfizer; QED Therapeutics
Research Funding - Exelixis; Five Prime Therapeutics; Genentech; Incyte; Merck
Travel, Accommodations, Expenses - Exelixis; QED Therapeutics
 
Howard John Lim
Honoraria - Amgen; AstraZeneca Canada; BMS Canada; Eisai; Ipsen; Merck; Roche Canada; Taiho Pharmaceutical
Research Funding - Roche (Inst); Taiho Pharmaceutical (Inst)
 
Theodore S. Hong
Stock and Other Ownership Interests - PanTher Therapeutics
Consulting or Advisory Role - Boston Scientific; Merck; Novocure; Syndax; Synthetic Biologics
Research Funding - AstraZeneca (Inst); Bristol Myers Squibb (Inst); IntraOp (Inst); Ipsen (Inst); Taiho Pharmaceutical (Inst); Tesaro (Inst)
 
Norman Wolmark
Research Funding - Genentech (Inst)
 
Thomas J. George
Consulting or Advisory Role - Pfizer; Tempus
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); BioMed Valley Discoveries (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Ipsen (Inst); Lilly (Inst); Merck (Inst); OncoC4 (Inst); Seagen (Inst)